Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals promising five-year results.

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

The U.S. Food and Drug Administration has granted approval to Merck & Co. (NYSE:MRK) for the use of KEYTRUDA and KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, to treat ...

Merck MRK is focusing on driving its long-term growth with its new products and a promising set of pipeline candidates as its blockbuster PD-L1 inhibitor, Keytruda, faces patent expiration in 2028.

Sept 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's (MRK.N), opens new tab blockbuster cancer therapy Keytruda that can be ...